United State Food and Drug Administration (USFDA) has completed Post-marketing Adverse Drug Experience (PADE) inspection at Marksans Pharma’s Goa, Verna manufacturing facility. The inspection closed with two observations. The inspection was conducted from July 31, 2023 to August 04, 2023. The inspection included comprehensive scrutiny of practices and procedures for reporting of adverse events of Marksans' marketed products.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
